Watch the recording of our PHGPS webinar exploring how patient associations can use the new Data Dashboard to understand global patient insights, support local action, and help shape PHGPS Phase 2.
Pulmonary arterial hypertension (PAH) is a progressive illness that may require therapy with parenteral prostacyclin pathway agents (PPA) (epoprostenol and treprostinil). These parenteral PPA's are continuous ambulatory infusions that require a high level of skill and knowledge to maintain safety and effectiveness.
The optimal use of vasoactive medications in patients with pulmonary arterial hypertension with shock remains unknown. Using a national database, we benchmarked initial vasoactive practices.
Preterm birth survivors reaching adulthood are a growing population, with bronchopulmonary dysplasia (BPD), the chronic lung disease of prematurity, common among this cohort. Infants with BPD are at increased risk for pulmonary vascular disease (PVD) including the development of pulmonary hypertension (PH).
Pulmonary hypertension (PH) is defined by elevated mean pulmonary arterial pressure (mPAP). Pulmonary vascular resistance (PVR) and SvO2 (mixed venous oxygenation), measured by right heart catheterization (RHC), are key determinants of disease severity and prognosis.
The gut microbiota has been implicated in pulmonary vascular diseases, yet a direct causal link to pulmonary embolism (PE) remains unestablished. This study aimed to investigate the causal effects of gut microbiota on PE and to explore the mediating role of circulating metabolites in this relationship.
We aimed to evaluate the role of medical therapy before and after balloon pulmonary angioplasty (BPA) for non-operable chronic thromboembolic pulmonary hypertension (CTEPH) in the modern management era.
Neonates and infants with FOXF1 mutation develop alveolar capillary dysplasia with misalignment of pulmonary veins (ACD/MPV), which is typically considered a uniformly fatal neonatal lung disorder due to marked hypoxemic respiratory failure with severe pulmonary hypertension (PH).
Explore how sex differences, estradiol, and oestrogen receptor α influence right ventricular angiogenesis and adaptation to pressure overload. Ketul Chaudhary and Jiajun Li share emerging research into the mechanisms that may protect right heart function in PH.
Pulmonary arterial hypertension (PAH) is a rare and progressive disease characterized by remodeling of the pulmonary vasculature, which leads to increased pulmonary artery pressure and ultimately right ventricular failure. Although Japanese guidelines recommend combination therapy, real-world data show inconsistencies in its implementation.
